Physician profile

William A Morowitz

Pulmonary Disease · Cherry Hill, NJ

NPI 1144289315

$2,309.98

in general payments reported to CMS, 2019-2025

19 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $851.55 2019-2021
Astrazeneca Pharmaceuticals Lp $410.06 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $241.82 2019-2021
Regeneron Healthcare Solutions, INC. $146.25 2019-2022
Mylan Specialty L.P. $133.29 2019-2021
Philips North America LLC $130.25 2019-2021
Insmed, INC. $86.87 2019-2021
Electromed, INC. $80.76 2019-2021
Jazz Pharmaceuticals INC. $40.97 2020-2021
Genentech USA, INC. $33.64 2019
Sunovion Pharmaceuticals INC. $29.78 2019
Grifols USA, LLC $29.67 2019-2021
United Therapeutics Corporation $17.28 2021
Shire North American Group INC $14.97 2019
Nabriva Therapeutics, Plc $14.24 2021
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Circassia INC. $12.92 2019
Harmony Biosciences LLC $12.32 2021
Teva Pharmaceuticals USA, INC. $12.23 2021
Merck Sharp & Dohme LLC $11.11 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William A Morowitz

$2,309.98

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/143034/william-a-morowitz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.